Edition:
United States

Incyte Corp (INCY.OQ)

INCY.OQ on NASDAQ Stock Exchange Global Select Market

65.03USD
15 Nov 2018
Change (% chg)

-- (--)
Prev Close
$65.03
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
557,922
52-wk High
$108.25
52-wk Low
$58.33

Select another date:

Thu, Nov 8 2018

Incyte loses trade-secret case against Flexus over cancer drug

A Delaware state court jury has rejected pharmaceutical company Incyte Corp's claims that rival Flexus Biosciences Inc was unjustly enriched by stealing cancer drug research trade secrets from it before Bristol-Myers Squibb Co acquired Flexus in 2015.

BRIEF-Incyte's Mid-stage Geometry Mono-1 Trial Of Investigational Medicine Capmatinib Shows Positive Results

* PHASE 2 GEOMETRY MONO-1 TRIAL OF INVESTIGATIONAL MEDICINE CAPMATINIB SHOWS POSITIVE RESULTS IN PATIENTS WITH MET-MUTATED ADVANCED NSCLC

FDA approves lower dose of Lilly-Incyte arthritis drug

The U.S. Food and Drug Administration on Friday approved the lower dose of a rheumatoid arthritis drug developed by Eli Lilly and Incyte Corp, but declined to approve its higher and more lucrative dose.

FDA approves lower dose of Lilly-Incyte arthritis drug

June 1 The U.S. Food and Drug Administration on Friday approved the lower dose of a rheumatoid arthritis drug developed by Eli Lilly and Incyte Corp, but declined to approve its higher and more lucrative dose.

Select another date: